GSE211781
LNCAP in-vitro treatment with androgen receptor targeting drugs
Gene expression in LNCaP cells after treatment with the androgen receptor targeting drugs bicalutamide (BIC), enzalutamide (ENZ) and apalutamide (ARN) in the presence or absence of dihydrotestosterone (DHT). Overall design: 16 samples, biological duplicates of LNCaP cells treated with bicalutamide (BIC), enzalutamide (ENZ) or apalutamide (ARN) in the presence or absence of dihydrotestosterone (DHT), respectively.